Creating uniform-sized tumor organoids for personalized cancer treatment
A micro-dissection platform for generating uniform-sized patient-derived tumor organoids (PDOs) for personalized cancer therapy
This study is working on a new way to create tiny models of your tumor that include important immune cells, so doctors can better understand how your body might respond to different cancer treatments and find the best options for you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10897241 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to create patient-derived tumor organoids (PDOs) that accurately reflect the patient's tumor environment. By using mechanical dissection to generate uniform-sized tumor fragments, the study aims to preserve important immune cells alongside tumor cells, which is crucial for testing personalized immunotherapies. The PDOs will allow for high-throughput drug screening to predict how individual patients might respond to various cancer treatments. This innovative approach addresses previous limitations in modeling immune responses in cancer therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who are seeking personalized cancer treatment options.
Not a fit: Patients with hematological cancers or those who are not undergoing tumor resection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments by accurately predicting patient responses to therapies.
How similar studies have performed: Other research has shown promise in using patient-derived organoids for drug response prediction, but this specific approach of preserving immune cells is novel.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Tang, Sindy Kam-Yan — Stanford University
- Study coordinator: Tang, Sindy Kam-Yan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.